Heron Therapeutics Inc HRTX:NASDAQ (Common Stock)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 7.52 | 0.03 0.40% | 141,221 | 139.6K |
Latest News Headlines for Heron Therapeutics Inc
Latest Annual and Quarterly SEC Filings
More FilingsCompany Background
Heron Therapeutics Inc, formerly A.P. Pharma, Inc. is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The Company's lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company's Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
collapse, right-facing arrow indicating collapsed view of sectionOverview
| Bid | Size | -- | -- |
|---|---|
| Ask | Size | -- | -- |
| Price Open | 7.48 |
| Previous Close | 7.52 |
| Day High | -- |
| Day Low | -- |
| 52 Week High | 3/20/2014 | 15.8188 |
| 52 Week Low | 10/9/2013 | 6.70 |
| % Off 52 Week High | -52.46% |
| % Off 52 Week Low | 12.24% |
| Beta (5 Yr) | 0.48 |
| Volatility Avg | 10/8/2014 | 56.12 |
| 10-Day Avg. Volume | 139,554 |
| Market data is delayed by at least 20 minutes. | |
collapse, right-facing arrow indicating collapsed view of sectionFundamentals
| EPS (TTM) | 6/30/2014 | -3.11 |
|---|---|
| P/E Ratio | 6/30/2014 | -- |
| Market Cap | Micro Cap | 217M |
| Shares Outstanding | 28.91M |
| Float | 28.7M |
collapse, right-facing arrow indicating collapsed view of sectionDividends
| Dividend Yield | -- |
|---|---|
| Ex-Date | -- |
| Dividend Announcement | -- |
| Date of Record | -- |
| Payable | -- - -- |
| Payable Date | -- |
Peers Information HelpHRTX Heron Therapeutics Inc vs. Peers
| Peers | |
|---|---|
HRTX Heron Therapeutics Inc | -15.51% |
Pacira Pharmaceuticals Inc | 76.26% |
DURECT Corporation | -23.12% |
HRTX Heron Therapeutics Inc | 0.00% |
Pacira Pharmaceuticals Inc | -- |
DURECT Corporation | -- |
HRTX Heron Therapeutics Inc | 0.40% |
Pacira Pharmaceuticals Inc | 3.87% |
DURECT Corporation | 0.00% |